-
India Rentomojo, IPO $131M

Rentomojo Limited — Company Analysis Deep Dive · India Consumer-Tech IPO Coverage Rentomojo India’s leading furniture-and-appliance rental subscription platform — initiating coverage on the BSE listing (544915): profitable compounder or VC liquidity event dressed as a growth IPO? ₹1,255.57 Cr IPO Issue Size +19.4% Listing-Day Pop (NSE) 253.8K+ Live Subscribers ₹104.3 Cr FY26 Net Profit…
-
인도 Rentomojo, IPO $131M

-
Spain Fever, Growth $250M

Fever — Company Analysis Deep Dive · Live-Entertainment Tech / Growth-Equity Analysis Fever A Spanish-founded platform betting on what AI cannot replace — we unpack the record $250M round led by EQT $250M 2026 EQT-Led Round 55 Countries of Operation 3x+ 3-Yr Revenue Growth (Co. Disclosed) 2014 Current Founding Team Formed 👥 Section 01 Founder…
-
스페인 Fever, Growth $250M

-
China D-Robotics, Series C $400M

D-Robotics Company Analysis Deep Dive · Robotics Infrastructure Analysis D-Robotics (地瓜机器人) A chip-and-software infrastructure company positioning itself as the “Wintel of robotics” — a Horizon Robotics spin-out betting on silicon over robot bodies $400M Series C (Sep 2026, per company) 8M+ Sunrise™ chip units shipped, cumulative $770M+ Disclosed capital raised, A–C 2024 Independent entity incorporated…
-
중국 D-Robotics, Series C $400M

-
Ridgeline, Series E $250M

Ridgeline — Company Analysis Deep Dive · Fintech / Enterprise SaaS Analysis Ridgeline The AI-native investment management platform — a founder’s bid for a third IPO by re-architecting legacy buy-side infrastructure $1.425B Latest Valuation (Sep 2026) $250M Series E Raise $750B+ AUM/AUA Committed 600+ Headcount 👤 Section 01 Founder Background & Origin Story Ridgeline, Inc.…
-
릿지라인, Series E $250M

-
Sling Therapeutics, Series C $123M

Sling Therapeutics — Company Analysis Deep Dive · Ophthalmic Autoimmune Biotech Analysis Sling Therapeutics An Ann Arbor-based clinical-stage biotech challenging the injectable standard of care in thyroid eye disease with the first late-stage oral IGF-1R inhibitor $123M Series C Raised Fast Track FDA Designation 52% Phase 2b/3 Responder Rate 2022 Public Launch 👥 Section 01…
-
슬링 테라퓨틱스, Series C $123M

Sling Therapeutics 기업 분석 Deep Dive · Ophthalmic Autoimmune Biotech Analysis Sling Therapeutics 최초의 경구용 IGF-1R 억제제로 갑상선 눈병증(TED) 시장의 주사제 패러다임에 도전하는 앤아버 소재 임상 단계 바이오텍 $123M Series C 조달액 Fast Track FDA 지정 52% Phase 2b/3 반응률(PRR) 2022 공식 출범 👥 Section 01 창업자 배경 및 설립 스토리 Sling Therapeutics는 미시간대(University of…
